Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

AJ1-11095, a potent and highly selective type-II JAK2 inhibitor, shows enhanced therapeutic efficacy as compared with type-I JAK2 inhibitor ruxolitinib in models of myeloproliferative neoplasms (MPNs)

View Full Paper
Ask AI
Bookmark
Share

Authors

ZZZachary ZaroogianMWMatthew WereskiRLRoss L. Levine

Discussion

Loading...

Member takes

Overview

Preclinical investigation reveals AJ1-11095 improves therapeutic efficacy in myelofibrosis, reducing mutant allele fraction compared to ruxolitinib.

Key Points

  • AJ1-11095 improves therapeutic efficacy in myelofibrosis compared to ruxolitinib, showing reduced mutant allele burden.
  • Platelet counts improved significantly in AJ1-11095-treated models, with enhanced therapeutic outcomes noted over ruxolitinib.
  • Observational analysis across transgenic animal models demonstrated AJ1-11095's superior action against MPNs over type-I inhibitors.
  • These findings support the potential of AJ1-11095 as an effective therapy for patients with refractory myelofibrosis.

Cite This Study

Zaroogian et al. (2025) studied this question.

synapsesocial.com/papers/69362f604fa91c937236dd5ahttps://doi.org/10.1182/blood-2025-1983
View Full Paper
Ask AI
Bookmark
Share